Published: June 02, 2026, 04:58 UTC
A Year of Treatment, Years of Protection: Abatacept Delayed Rheumatoid Arthritis Onset for Up to Four Years
In medicine, the difference between treating a disease and preventing it is measured in years. For rheumatoid arthritis — a chronic autoimmune condition that affects roughly 1% of the global population — the distinction has been elusive. Drugs can manage symptoms once the disease appears. But can you intervene before it starts, and if so, for how long does the protection last?
The ALTO trial — a long-term follow-up of the earlier APIPPRA study — provides an answer that is both precise and remarkable. A year of treatment with abatacept (Orencia), a T-cell costimulation modulator, delayed the onset of rheumatoid arthritis in at-risk individuals by up to four years after the drug was stopped. The results were published in the March 2026 issue of The Lancet Rheumatology.
The Study Design
APIPPRA (Arthritis Prevention In the Preclinical Phase of Rheumatoid Arthritis with Abatacept) was a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial conducted across 28 hospital sites in the UK and the Netherlands. Between December 2014 and January 2019, it enrolled 213 participants who were at high risk of developing rheumatoid arthritis — defined by the presence of anti-citrullinated protein antibodies (ACPAs) and joint pain, but without clinical synovitis (the joint inflammation that defines active RA).
Participants received either weekly subcutaneous abatacept (110 patients) or placebo (103 patients) for one year, followed by 12 months of observation. The primary endpoint was the development of clinically detectable RA.
The ALTO follow-up extended that observation to between 4 and 8 years after enrollment, with participants and clinical assessors remaining masked to the original treatment assignment. Of the original 213 participants, 143 enrolled in the follow-up (71 from the abatacept group, 72 from the placebo group).
The Results
In the original APIPPRA trial, abatacept reduced the risk of progressing to RA by about half during the treatment period. But the ALTO follow-up asked a different question: what happens after the drug is gone?
The answer: the benefit persisted.
Participants who had received just one year of abatacept remained protected from RA onset for years afterward. On average, the treatment provided approximately 10 months of additional RA-free survival compared with placebo. At the far end of the follow-up window, some participants had not developed RA for up to four years after the single year of treatment ended.
“The durability of the effect was unexpected,” says Prof. Andrew Cope of King’s College London, lead author of the study. “A one-year intervention that changes the trajectory of disease risk for years afterward suggests we’re not just suppressing symptoms — we’re altering the underlying immune process.”
At six years of follow-up, only 29% of at-risk participants had not progressed to RA overall, reflecting the high baseline risk of the study population. But the abatacept group consistently fared better. The hazard ratio for progression to RA in the abatacept group versus placebo was approximately 0.6, meaning a roughly 40% reduction in the risk of developing RA over the entire follow-up period.
The Mechanism
Abatacept is a CTLA4-Ig fusion protein. It works by binding to CD80 and CD86 receptors on antigen-presenting cells, blocking their interaction with CD28 on T cells. This inhibits T-cell activation — the process by which the immune system’s T cells, having been erroneously programmed to recognize self-antigens, orchestrate the inflammatory attack on joint tissue.
The fact that a year of this intervention produces a multi-year durable effect suggests that abatacept may be doing more than transiently suppressing T-cell activity. It may be resetting the immune balance — allowing protective regulatory mechanisms to re-establish control over autoreactive T cells in a way that persists after the drug is cleared.
“This tells us that there is a window early in the disease process where the autoimmune trajectory can be durably modified,” says Cope. “Once clinical arthritis is established, the disease may be much harder to redirect.”
Implications
The ALTO results have immediate implications for how physicians think about pre-RA. Current guidelines do not recommend treating at-risk individuals preventively — in part because the risk-benefit calculus was unclear. A drug that delays or prevents onset for years shifts that calculus.
“These data argue for a paradigm shift in RA management,” says Cope. “We should be identifying individuals at risk — those with ACPAs and joint pain — and intervening early. The window may be narrow, but if you catch it, the benefit lasts.”
The results also raise a practical question: if a year of abatacept delays RA for up to four years, could an intermittent re-treatment strategy extend that protection indefinitely? That question will need its own trial.
The study was funded by Bristol Myers Squibb, which manufactures abatacept. The ALTO investigators included researchers from King’s College London, the University of Birmingham, Leiden University Medical Center, the University of Glasgow, Newcastle University, the University of Oxford, the University of Leeds, and the University of Manchester.
Reference: Cope, A. P., Jasenecova, M., Vasconcelos, J. C., et al. (2026). Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomized, double-blind, placebo-controlled trial. The Lancet Rheumatology, 8(3), e171–e180. DOI: 10.1016/S2665-9913(25)00371-6.